Top-News

Cumberland Pharmaceuticals Aktie News

Aktie
WKN:  A0RC46 ISIN:  US2307701092 US-Symbol:  CPIX Branche:  Pharmazeutika Land:  USA
2,35 $
+0,00 $
0,00%
2,0168 € 04.12.25
Depot/Watchlist
Marktkapitalisierung *
25,67 Mio. €
Streubesitz
34,79%
KGV
-5,15
Index-Zuordnung
-

Cumberland Pharmaceuticals News

04.11.25 - PR Newswire
CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH
CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-​TO-DATE REVENUE GROWTH PR Newswire
28.10.25 - PR Newswire
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE PR Newswire
20.10.25 - PR Newswire
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO PR Newswire
13.10.25 - PR Newswire
CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.
CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC. PR Newswire
01.10.25 - PR Newswire
CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO
CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO PR Newswire
29.09.25 - PR Newswire
TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA
TABUK LAUNCHES VIBATIV® FDA-​APPROVED ANTIBIOTIC WITH LIFE-​SAVING POTENTIAL IN SAUDI ARABIA PR Newswire
05.08.25 - PR Newswire
Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-​to-Date PR Newswire
04.08.25 - PR Newswire
CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK
CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK PR Newswire
29.07.25 - PR Newswire
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE PR Newswire
23.06.25 - PR Newswire
Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference PR Newswire
27.05.25 - PR Newswire
NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS
NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-​SPARING PAIN MANAGEMENT IN OLDER ADULTS PR Newswire
13.05.25 - PR Newswire
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH PR Newswire
06.05.25 - PR Newswire
Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025 PR Newswire
29.04.25 - PR Newswire
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE PR Newswire
19.03.25 - PR Newswire
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
FIGHT DMD Trial Results Selected for Late-​Breaking Presentation at MDA Clinical & Scientific Conference PR Newswire
04.03.25 - PR Newswire
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth PR Newswire
25.02.25 - PR Newswire
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS PR Newswire
18.02.25 - PR Newswire
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA PR Newswire
04.02.25 - PR Newswire
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease PR Newswire
09.12.24 - PR Newswire
FDA APPROVES ACETADOTE® sNDA
FDA APPROVES ACETADOTE® sNDA PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »